hello@apconix.com

About Richard Knight

Dr Richard Knight PhD, ERT. A co-founder of ApconiX, Richard is an expert toxicologist with more than 20 years of drug development experience gained in AstraZeneca, where he was part of the Drug Safety and Oncology Leadership Teams. Richard has worked on projects in multiple therapy areas involving small molecules, biologics, proteins and oligonucleotides. He has an in-depth understanding of drug discovery and drug development and has been directly involved in bringing over 35 new candidate drugs to clinical trials and 6 to marketing approval. He uses his extensive experience to bring an innovative, science-led and pragmatic approach to the design and delivery of nonclinical safety programmes.

ApconiX Achieves Five-Fold Turnover Boost

The business has just received the accolade of Start-Up of the Year at the 17th awards hosted by BioNow, the northern England bio-medical and life sciences membership organisation. The company’s early success is based on delivering expertise in safety toxicology and ion channel electrophysiology to a changing pharmaceutical sector, in which more companies are [...]

By |2025-08-20T15:03:46+01:00December 7th, 2017|Press|Comments Off on ApconiX Achieves Five-Fold Turnover Boost
Read More

Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure? 

Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure? Abstract: We have previously reported the profile of target organs (defined as organs showing histopathological changes) in rodent and non-rodent toxicity studies conducted prior to first-time-in-man (FTiM) for 77 AstraZeneca candidate drugs [...]

By |2023-01-18T15:10:02+00:00December 1st, 2015|Toxicology, Publications|Comments Off on Target organ profiles in toxicity studies supporting human dosing: Does severity progress with longer duration of exposure? 
Read More

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.

Phase I dose-escalation study of AZD7762 Abstract: Purpose AZD7762 is a Chk1 kinase inhibitor which increases sensitivity to DNA-damaging agents, including gemcitabine. We evaluated the safety of AZD7762 monotherapy and with gemcitabine in advanced solid tumor patients. Experimental design In this Phase I study, patients received intravenous AZD7762 on [...]

By |2023-01-18T14:38:37+00:00March 20th, 2014|Publications, Toxicology|Comments Off on Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in patients with advanced solid tumors.
Read More
Copyright ApconiX | All Rights Reserved | Website by Greenlight Web
Go to Top